Identification of Genomic Signatures for Colorectal Cancer Survival Using Exploratory Data Mining

Justin J. Hummel,Danlu Liu,Erin Tallon,John Snyder,Wesley Warren,Chi-Ren Shyu,Jonathan Mitchem,Rene Cortese

DOI: https://doi.org/10.3390/ijms25063220

IF: 5.6

2024-03-12

International Journal of Molecular Sciences

Abstract:Clinicopathological presentations are critical for establishing a postoperative treatment regimen in Colorectal Cancer (CRC), although the prognostic value is low in Stage 2 CRC. We implemented a novel exploratory algorithm based on artificial intelligence (explainable artificial intelligence, XAI) that integrates mutational and clinical features to identify genomic signatures by repurposing the FoundationOne Companion Diagnostic (F1CDx) assay. The training data set (n = 378) consisted of subjects with recurrent and non-recurrent Stage 2 or 3 CRC retrieved from TCGA. Genomic signatures were built for identifying subgroups in Stage 2 and 3 CRC patients according to recurrence using genomic parameters and further associations with the clinical presentation. The summarization of the top-performing genomic signatures resulted in a 32-gene genomic signature that could predict tumor recurrence in CRC Stage 2 patients with high precision. The genomic signature was further validated using an independent dataset (n = 149), resulting in high-precision prognosis (AUC: 0.952; PPV = 0.974; NPV = 0.923). We anticipate that our genomic signatures and NCCN guidelines will improve recurrence predictions in CRC molecular stratification.

biochemistry & molecular biology,chemistry, multidisciplinary

What problem does this paper attempt to address?

The problem that this paper attempts to solve is how to predict tumor recurrence through genomic features in colorectal cancer (CRC), especially for stage 2 patients. Although the current clinicopathological manifestations are crucial for formulating postoperative treatment plans, their prognostic value in stage 2 CRC is low. Therefore, the authors have developed a new exploratory algorithm based on artificial intelligence (explainable artificial intelligence, XAI), combined with mutations and clinical features, and reused the FoundationOne Companion Diagnostic (F1CDx) test to identify genomic features, in order to improve the recurrence prediction accuracy for stage 2 CRC patients.

Specifically, the main objectives of the study include:
1. **Identify genomic features**: Construct genomic features that can distinguish between recurrent and non - recurrent patients by integrating mutation and clinical data.
2. **Improve prediction accuracy**: Verify the prediction performance of these genomic features in an independent dataset, especially for their application in stage 2 CRC patients.
3. **Assist clinical decision - making**: Propose a diagnostic framework based on F1CDx to assist clinicians in more accurately assessing the recurrence risk of stage 2 CRC patients.

Through these objectives, the study aims to improve the molecular stratification of stage 2 CRC patients, thereby optimizing treatment selection and prognostic evaluation.